🔗 Visit the ClinicalTrials.gov page for NCT00970138
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. | J Clin Oncol | 2013 | 2.69 |
| 2 | Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. | BMC Cancer | 2010 | 1.35 |
| 3 | Apatinib for molecular targeted therapy in tumor. | Drug Des Devel Ther | 2015 | 0.98 |
| 4 | Clinical management of advanced gastric cancer: the role of new molecular drugs. | World J Gastroenterol | 2014 | 0.92 |
| 5 | Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. | Onco Targets Ther | 2015 | 0.89 |
| 6 | The progress of targeted therapy in advanced gastric cancer. | Biomark Res | 2013 | 0.89 |
| 7 | Gastric Cancer: New Drugs - New Strategies. | Gastrointest Tumors | 2015 | 0.78 |